Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
Ann Transl Med
.
2019 Jul;7(Suppl 3):S140.
doi: 10.21037/atm.2019.06.35.
Authors
Willemijn S M E Theelen
1
,
Paul Baas
1
Affiliation
1
Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
PMID:
31576347
PMCID:
PMC6685838
DOI:
10.21037/atm.2019.06.35
No abstract available
Publication types
Editorial
Comment